RxDoctor Payments Data

Arnold Blaustein, MD

Hematology & Oncology · Miami Beach, FLNPI 1497743124

Payments from drug & device makers

$70,326in general payments, 2019–2025

Across 1,004 payments — averaging $70.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$45K
  • Gilead$9K
  • Bristol Myers Squibb$2K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Novartis$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$7,29027%
  • Travel & lodging$1,0584%
  • Food & beverage$17,38765%
  • Education$8283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck68$44,826
Gilead(2 entities)23$8,780
Bristol Myers Squibb100$1,958
Johnson & Johnson(2 entities)84$1,346
AstraZeneca(2 entities)63$1,234
Novartis72$1,201
Pfizer54$924
Genentech USA, Inc.50$881
EMD Serono, Inc.74$673
Astellas Pharma US Inc25$549
AbbVie24$545
Incyte Corporation26$542
Daiichi Sankyo Inc.21$480
E.r. Squibb & Sons, L.L.C.25$461
Amgen26$412
Lilly USA, LLC14$398
Takeda Pharmaceuticals U.S.A., Inc.9$349
Eisai Inc.17$314
Beigene USA, Inc.17$297
Sumitomo Pharma America, Inc.11$257
Pharmacyclics LLC, An Abbvie Company13$250
Sanofi12$234
Seagen Inc.14$231
Epizyme, Inc.5$187
Regeneron Healthcare Solutions, Inc.9$186
Tempus AI, Inc9$166
Boehringer Ingelheim6$135
Clovis Oncology, Inc.6$126
Morphosys, US Inc.7$123
Bayer7$122
Ipsen Biopharmaceuticals, Inc7$121
Exelixis Inc.7$119
Karyopharm Therapeutics Inc.6$111
Myriad Genetic Laboratories, Inc.6$105
Sun Pharmaceutical Industries Inc.5$103
Deciphera Pharmaceuticals Inc.5$102
Taiho Oncology, Inc.5$97
EUSA Pharma (US) LLC5$94
Dova Pharmaceuticals5$92
Aurobindo Pharma USA, Inc.6$82
Adaptive Biotechnologies Corporation4$78
Kyowa Kirin, Inc.4$73
Myovant Sciences Inc.3$72
Springworks Therapeutics, Inc.3$65
Mirati Therapeutics, Inc.3$63
AVEO Pharmaceuticals, Inc.2$60
Jazz Pharmaceuticals Inc.3$60
Foundation Medicine, Inc.2$53
CTI Biopharma Corp.3$52
Rigel Pharmaceuticals, Inc.3$50
Acceleron Pharma, Inc.3$50
Genmab U.S., Inc.2$46
Servier Pharmaceuticals LLC2$42
ADC Therapeutics America, Inc.2$41
Sobi, Inc2$40
Sanofi-aventis U.S. LLC2$35
Dendreon Pharmaceuticals LLC1$31
Teva Pharmaceuticals USA, Inc.2$30
Geron Corporation1$25
Tersera Therapeutics LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,326 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$41,307
Medicare patients
165
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate37$604,397
ImbruvicaIbrutinib30$527,790
OjjaaraMomelotinib Dihydrochloride14$393,363
JakafiRuxolitinib Phosphate16$288,261
RetacritEpoetin Alfa-Epbx11$19,099
XareltoRivaroxaban15$15,236
Hydroxyurea31$1,150
Allopurinol28$218
Potassium Chloride13$101
Alprazolam12$61
Prednisone28$50
Anastrozole12$45
Furosemide12$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$1,234$604,39737 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$250$527,79030 claims
Incyte CorporationJakafi$542$288,26116 claims
PfizerRetacrit$924$19,09911 claims
Johnson & JohnsonXarelto$1,346$15,23615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →